izpis_h1_title_alt

Serum calretinin as a biomarker in malignant mesothelioma
ID Zupanc, Cita (Author), ID Franko, Alenka (Author), ID Štrbac, Danijela (Author), ID Dodič-Fikfak, Metoda (Author), ID Kovač, Viljem (Author), ID Dolžan, Vita (Author), ID Goričar, Katja (Author)

.pdfPDF - Presentation file, Download (938,58 KB)
MD5: 8D85F23F783592C588B88965A15C467C
URLURL - Source URL, Visit https://www.mdpi.com/2077-0383/10/21/4875 This link opens in a new window

Abstract
The early diagnosis of malignant mesothelioma (MM) could improve the prognosis of MM patients. To confirm an MM diagnosis, an immunohistochemical analysis of several tumor tissue markers, including calretinin, is currently required. Our aim is to evaluate serum calretinin as a potential biomarker in asbestos-related diseases, especially in MM. Our study includes 549 subjects: 164 MM patients, 117 subjects with asbestosis, 195 subjects with pleural plaques and 73 occupationally asbestos-exposed subjects without asbestos-related diseases. The serum calretinin concentration was determined with a commercially available enzyme immunoassay. Data on the soluble mesothelinrelated peptides (SMRP) concentration are available from previous studies. MM patients had a significantly higher calretinin concentration than subjects without disease, subjects with pleural plaques or subjects with asbestosis (all p < 0.001). The histological type was significantly associated with serum calretinin: patients with sarcomatoid MM had lower calretinin than patients with the epithelioid type (p = 0.001). In a ROC curve analysis, the area under the curve for calretinin concentration predicting MM was 0.826 (95% CI = 0.782–0.869; p < 0.001). At the cutoff value of 0.32 ng/mL, sensitivity was 0.683, while specificity was 0.886. The combination of calretinin and SMRP had the highest predictive value. Calretinin is a useful biomarker that can distinguish MM from other asbestos-related diseases and could, therefore, contribute to an earlier non-invasive diagnosis of MM.

Language:English
Keywords:malignant mesothelioma, calretinin, asbestos-related disease, biomarker
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2021
Number of pages:11 str.
Numbering:Vol. 10, iss. 21, art. 4875
PID:20.500.12556/RUL-136448 This link opens in a new window
UDC:616-057
ISSN on article:2077-0383
DOI:10.3390/jcm10214875 This link opens in a new window
COBISS.SI-ID:83032579 This link opens in a new window
Publication date in RUL:04.05.2022
Views:445
Downloads:106
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Journal of clinical medicine
Shortened title:J. clin. med.
Publisher:MDPI
ISSN:2077-0383
COBISS.SI-ID:5405759 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:01.11.2021

Secondary language

Language:Slovenian
Keywords:maligni mezoteliom, kalretinin, bolezen, povezana z azbestom

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0170
Name:Molekulski mehanizmi uravnavanja celičnih procesov v povezavi z nekaterimi boleznimi pri človeku

Funder:ARRS - Slovenian Research Agency
Project number:L3-8203
Name:Serumski, genetski in epigenetski označevalci tveganja za nastanek, napredovanja in odgovora na zdravljenje bolezni, povezanih z izpostavljenostjo azbestu

Funder:ARRS - Slovenian Research Agency
Project number:L3-2622
Name:Biološki označevalci nastanka, napredovanja in odgovora na zdravljenje bolezni, povezanih z izpostavljenostjo azbestu

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back